Read

Members
Client Resources
Pharmacy + Provider Resources
Drug Recalls
Events

Who we are
Our solutions
Read, watch, listen
Pharmacy
Careers

Members
Client Resources
Pharmacy + Provider Resources
Drug Recalls
Events

Home
Read, watch, listen
Read

Explore what's trending at Prime

https://www.primetherapeutics.com/w/prime-therapeutics-leading-research-shows-only-1-in-12-remain-on-a-glp-1-drug-for-obesity-at-three-years Example Link

GLP-1, Press Releases

Prime Therapeutics’ leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

June 25, 2025

https://www.primetherapeutics.com/w/prime-therapeutics-leading-research-shows-only-1-in-12-remain-on-a-glp-1-drug-for-obesity-at-three-years

Press Releases

Prime Therapeutics’ leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

June 25, 2025

https://www.primetherapeutics.com/w/reuters-exclusive-new-data-show-most-us-patients-now-stay-on-wegovy-zepbound-after-a-year https://www.reuters.com/business/healthcare-pharmaceuticals/new-data-show-most-us-patients-now-stay-wegovy-zepbound-after-year-2025-06-25/

In the News

Reuters: Exclusive: New data show most US patients now stay on Wegovy, Zepbound after a year

June 25, 2025

https://www.primetherapeutics.com/w/oncology-insights-june-2025 /oncology-insights-june-2025

Research & Publications

Oncology Insights: June 2025

June 25, 2025

The Latest

Categories

PA Sub-Categories

https://www.primetherapeutics.com/w/prime-therapeutics-leading-research-shows-only-1-in-12-remain-on-a-glp-1-drug-for-obesity-at-three-years

Prime Therapeutics’ leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

June 25, 2025

https://www.primetherapeutics.com/w/prime-therapeutics-highlights-industry-leading-glp-1-research-at-amcp-2025

Prime Therapeutics highlights industry-leading GLP-1 research at AMCP 2025

March 31, 2025

https://www.primetherapeutics.com/w/prime-therapeutics-glp-1-research-year-2-cost-of-care-is-4-200-higher-for-patients-with-obesity

Prime Therapeutics GLP-1 research: Year-2 cost of care is $4,200 higher for patients with obesity

October 24, 2024

https://www.primetherapeutics.com/w/medical-benefit-drug-trend-prime-therapeutics-medical-pharmacy-trend-report-goes-behind-the-numbers-2024

Medical benefit drug trend: Prime Therapeutics Medical Pharmacy Trend Report™ goes behind the numbers

October 15, 2024

https://www.primetherapeutics.com/w/prime-therapeutics-bolsters-its-position-as-industry-leader-with-10-research-studies-at-amcp-nexus-2024

Prime Therapeutics bolsters its position as industry leader with 10 research studies at AMCP Nexus 2024

October 10, 2024

https://www.primetherapeutics.com/w/prime-therapeutics-announces-new-cost-effective-humira-biosimilar-solutions-offering-clients-flexibility-and-choice

Prime Therapeutics announces new, cost-effective Humira® biosimilar solutions, offering clients flexibility and choice

October 07, 2024

Showing 1 to 6 of 36

Categories

PA Sub-Categories

https://www.primetherapeutics.com/w/what-s-next-in-the-glp-1-pipeline-prime-s-clinical-team-shares-the-latest

What’s next in the GLP-1 pipeline? Prime’s clinical team shares the latest

June 18, 2025

https://www.primetherapeutics.com/w/prime-therapeutics-recognizes-migraine-and-headache-awareness-month

Prime Therapeutics recognizes Migraine and Headache Awareness Month

June 18, 2025

https://www.primetherapeutics.com/w/prime-therapeutics-identifies-addresses-misuse-of-asthma-inhaler-prescription-with-174k-impact

Prime Therapeutics identifies, addresses misuse of asthma inhaler prescription with $174K impact

April 29, 2025

https://www.primetherapeutics.com/w/national-drug-take-back-day-prioritizing-drug-safety-at-home

National Drug Take Back Day: Prioritizing drug safety at home

April 23, 2025

https://www.primetherapeutics.com/w/prime-therapeutics-identifies-misuse-of-diabetic-supplies-prescription

Prime Therapeutics identifies misuse of diabetic supplies prescription

April 22, 2025

https://www.primetherapeutics.com/w/icymi-catch-up-on-prime-s-educational-sessions-from-amcp-2025

ICYMI: Catch up on Prime’s educational sessions from AMCP 2025

April 17, 2025

Showing 1 to 6 of 59

Categories

PA Sub-Categories

https://www.primetherapeutics.com/w/prime-therapeutics-reimagines-migraine-treatment-with-innovative-solutions

Prime Therapeutics reimagines migraine treatment with innovative solutions

June 18, 2025

https://www.primetherapeutics.com/w/prime-careers-spotlight-june-2025 https://www.primetherapeutics.com/prime-careers-spotlight-june-2025

Prime Careers Spotlight: June 2025

June 16, 2025

https://www.primetherapeutics.com/w/prime-therapeutics-named-second-largest-private-company-headquartered-in-minnesota

Prime Therapeutics named second largest private company headquartered in Minnesota

June 13, 2025

https://www.primetherapeutics.com/w/prime-empowers-patients-with-multiple-sclerosis-through-personalized-support-cost-saving-tools

Prime empowers patients with multiple sclerosis through personalized support, cost-saving tools

May 30, 2025

https://www.primetherapeutics.com/w/prime-therapeutics-prioritizes-patient-centered-care-stays-ahead-of-oncology-trends

Prime Therapeutics prioritizes patient-centered care, stays ahead of oncology trends

May 27, 2025

https://www.primetherapeutics.com/w/prime-careers-spotlight-april-2025-duplicate-1 https://www.primetherapeutics.com/prime-careers-spotlight-may-2025

Prime Careers Spotlight: May 2025

May 20, 2025

Showing 1 to 6 of 121

Categories

PA Sub-Categories

https://www.primetherapeutics.com/w/prime-presents-at-isg-digital-business-summit-on-nov-14

Prime presents at ISG Digital Business Summit on Nov. 14

November 05, 2024

https://www.primetherapeutics.com/w/prime-presents-2024-medical-pharmacy-trend-report-webinar

Prime presents 2024 Medical Pharmacy Trend Report webinar on Oct. 24

October 01, 2024

https://www.primetherapeutics.com/w/prime-presents-at-amcp-nexus-2024

Prime presents at AMCP Nexus 2024 on Oct. 14–17

September 30, 2024

https://www.primetherapeutics.com/w/prime-presents-at-medicaid-drug-rebate-program-mdrp-summit-2024-on-sept-23-25

Prime presents at Medicaid Drug Rebate Program (MDRP) Summit 2024 on Sept. 23–25

September 23, 2024

https://www.primetherapeutics.com/w/prime-presents-at-72nd-annual-roy-a-bowers-conference

Prime presents at 72nd Annual Roy A. Bowers Conference on Oct. 22

September 16, 2024

https://www.primetherapeutics.com/w/prime-presents-at-glp-1-agonists-food-is-medicine-a-new-recipe-for-success-in-treating-obesity-a-briefing-for-congress-

Prime presents at: GLP-1 Agonists + Food is Medicine: A New Recipe for Success in Treating Obesity? A Briefing for Congress on Sept. 11

September 11, 2024

Showing 1 to 6 of 33

Categories

PA Sub-Categories

Reuters: Exclusive: New data show most US patients now stay on Wegovy, Zepbound after a year

June 25, 2025

https://www.primetherapeutics.com/w/minneapolis/st-paul-business-journal-minnesota-s-largest-private-companies https://www.bizjournals.com/twincities/subscriber-only/2025/06/12/minnesotas-largest-private-companies.html

Minneapolis/St. Paul Business Journal: Minnesota's Largest Private Companies

June 12, 2025

https://www.primetherapeutics.com/w/managed-healthcare-executive-matthew-helbling-pharm-d-video-interview-2025-mhe-emerging-leaders-in-healthcare- https://www.managedhealthcareexecutive.com/view/matthew-helbling-pharm-d-video-interview-2025-mhe-emerging-leaders-in-healthcare

Managed Healthcare Executive: Matthew Helbling, Pharm.D., Video Interview | 2025 MHE Emerging Leaders in Healthcare

June 04, 2025

https://www.primetherapeutics.com/w/pharmacy-podcast-network-asx-25-access-to-pharmacy-in-las-vegas-part-two https://www.youtube.com/watch?v=xTOhnTctptA

Pharmacy Podcast Network: ASX 25: Access to Pharmacy in Las Vegas, Part Two

May 22, 2025

https://www.primetherapeutics.com/w/managed-healthcare-executive-do-robots-have-a-place-in-healthcare-asembia-s-axs25-summit https://www.managedhealthcareexecutive.com/view/do-robots-have-a-place-in-healthcare-asembia-s-axs25-summit

Managed Healthcare Executive: Do Robots Have a Place in Healthcare? | Asembia's AXS25 Summit

April 30, 2025

https://www.primetherapeutics.com/w/managed-healthcare-executive-ai-is-a-physician-complement-not-replacement-expert-says-asembia-s-axs25-summit https://www.managedhealthcareexecutive.com/view/ai-is-a-physician-compliment-not-replacement-expert-says-asembia-s-axs25-summit

Managed Healthcare Executive: AI is a Physician Complement, Not Replacement, Expert Says | Asembia's AXS25 Summit

April 30, 2025

Showing 1 to 6 of 106

Categories

PA Research & Publications

https://www.primetherapeutics.com/w/oncology-insights-june-2025 /oncology-insights-june-2025

Oncology Insights: June 2025

June 25, 2025

https://www.primetherapeutics.com/w/fda-decisions-expected-july-2025 /fda-decisions-expected-july-2025

FDA Decisions Expected: July 2025

June 18, 2025

https://www.primetherapeutics.com/w/high-cost-therapy-profile-june-2025 /high-cost-therapy-profile-june-2025

High-Cost Therapy Profile: June 2025

June 18, 2025

https://www.primetherapeutics.com/w/trending-topics-drug-approvals-may-2025 /trending-topics-drug-approvals-may-2025

GLP-1 Pipeline Update: May 2025

May 27, 2025

https://www.primetherapeutics.com/w/high-cost-therapy-profile-may-2025 /high-cost-therapy-profile-may-2025

High-Cost Therapy Profile: May 2025

May 15, 2025

Showing 1 to 6 of 150

Login Portals

Members and Consumers
Clients and Health Plans
Pharmacy + Provider Resources

Compliance / Legal

Privacy Policy
Notice of Privacy Practices
Terms of Use
Nondiscrimination + Languages
Subrogation

Company

About us
Careers
News
Media

Read - Prime Therapeutics

About us

Corporate social responsibility

Solutions overview

Modern technology

Drug access

Clinical solutions

Condition management

Specialty drug management

Government solutions

Single-state programs

Watch

Listen

Home Delivery

Specialty Pharmacy

Navigate to

Back

Back

Back

Back

Explore what's trending at Prime

Prime Therapeutics’ leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

Prime Therapeutics’ leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

Reuters: Exclusive: New data show most US patients now stay on Wegovy, Zepbound after a year

Oncology Insights: June 2025

The Latest

Prime Therapeutics’ leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

Prime Therapeutics highlights industry-leading GLP-1 research at AMCP 2025

Prime Therapeutics GLP-1 research: Year-2 cost of care is $4,200 higher for patients with obesity

Medical benefit drug trend: Prime Therapeutics Medical Pharmacy Trend Report™ goes behind the numbers

Prime Therapeutics bolsters its position as industry leader with 10 research studies at AMCP Nexus 2024

Prime Therapeutics announces new, cost-effective Humira® biosimilar solutions, offering clients flexibility and choice

What’s next in the GLP-1 pipeline? Prime’s clinical team shares the latest

Prime Therapeutics recognizes Migraine and Headache Awareness Month

Prime Therapeutics identifies, addresses misuse of asthma inhaler prescription with $174K impact

National Drug Take Back Day: Prioritizing drug safety at home

Prime Therapeutics identifies misuse of diabetic supplies prescription

ICYMI: Catch up on Prime’s educational sessions from AMCP 2025

Prime Therapeutics reimagines migraine treatment with innovative solutions

Prime Careers Spotlight: June 2025

Prime Therapeutics named second largest private company headquartered in Minnesota

Prime empowers patients with multiple sclerosis through personalized support, cost-saving tools

Prime Therapeutics prioritizes patient-centered care, stays ahead of oncology trends

Prime Careers Spotlight: May 2025

Prime presents at ISG Digital Business Summit on Nov. 14

Prime presents 2024 Medical Pharmacy Trend Report webinar on Oct. 24

Prime presents at AMCP Nexus 2024 on Oct. 14–17

Prime presents at Medicaid Drug Rebate Program (MDRP) Summit 2024 on Sept. 23–25

Prime presents at 72nd Annual Roy A. Bowers Conference on Oct. 22

Prime presents at: GLP-1 Agonists + Food is Medicine: A New Recipe for Success in Treating Obesity? A Briefing for Congress on Sept. 11

Reuters: Exclusive: New data show most US patients now stay on Wegovy, Zepbound after a year

Minneapolis/St. Paul Business Journal: Minnesota's Largest Private Companies

Managed Healthcare Executive: Matthew Helbling, Pharm.D., Video Interview | 2025 MHE Emerging Leaders in Healthcare

Pharmacy Podcast Network: ASX 25: Access to Pharmacy in Las Vegas, Part Two

Managed Healthcare Executive: Do Robots Have a Place in Healthcare? | Asembia's AXS25 Summit

Managed Healthcare Executive: AI is a Physician Complement, Not Replacement, Expert Says | Asembia's AXS25 Summit

Oncology Insights: June 2025

FDA Decisions Expected: July 2025

High-Cost Therapy Profile: June 2025

Trending Topics & Drug Approvals: May 2025

GLP-1 Pipeline Update: May 2025

High-Cost Therapy Profile: May 2025

Login Portals

Compliance / Legal

Company